Clinical Trial Search

Primary: Cumulative Change in Weight (Kilograms) Per 40mg of IV Furosemide Equivalents, Adjusted for Baseline Weight — -0.31; -0.42 kg/40mg IV furosemide

Primary: Reduction in Episodic Oxygen Desaturation

Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL

Primary: Total Urine Sodium Output — 1082; 423 mmol of sodium — p=<0.001

Primary: Dyspnea — 1264; 1650 mmxh — p=0.18

Primary: Days Alive and Out of Hospital — 26.9; 25.4 Days Alive and Out of Hospital

Primary: Successful Decongestion — 79; 108 Participants

Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine

Primary: Patient Well Being, as Determined by a Visual Analog Scale — 4236; 4372.7; 4170.8; 4429.6 units on a scale

Primary: Short Physical Performance Battery (SPPB) at Month 3 — 6.9; 8.3 score on a scale — p=<0.0001

Primary: Effect of Thiamine Supplementation on Dyspnea — 34; 32 mm

Primary: Acetazolamide Arm: Natriuresis 24 h — 324; 300; 211; 190 mmol — p=0.515

Primary: Hospital Length of Stay — 7; 8 days

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: Percentage of Participants Experiencing Clinically Relevant Hypotension — 15.4; 16.7 Percent of participants

Primary: Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 6…

Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants

Primary: 6 Minute Walk Test — 224; 247 meters

Primary: Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid at 10 Weeks Post Randomization — 224; 248 Participants — p=0.099

Primary: Overall Safety of a Strategy Based on Subcutaneous Delivery of Furosemide in Inpatients and Outpatients as Measured by Number of Adverse Events — 4; 9; 16; 11 participants

Primary: Mortality, Days in Hospital & Decongestion — 54.68; 44.16 % wins — p=0.357

Primary: Median Urine Output at 24 Hours Post Randomization — 2910; 3150 mL

Primary: Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours — 20; 26 Participants — p=0.315

Primary: Optimization Potential Score — 2.9; 2.6 score on a scale

Primary: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP or Pulmonary Arterial Diastolic Pressure[PADP]) at 3 Hours — 27.7; 24.8; 29.7; -6.7 Millimeters of…

Primary: Evaluation of Mean Urine Output Volume During the Infusion Period — 2505; 2140 mL — p=0.04

Primary: Change in E/Ea Ratio — -4.55; -1.55; -3.16; -1.08 Unitless ratio — p=0.029

Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants

Primary: Left Ventricular Ejection Fraction Improvement — 4.5; -.3 percent change

Primary: Change in Cystatin C — .12; .11; .07 mg/L